We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+45.35%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$113M
AUM Growth
-$3.52M
Cap. Flow
-$1.17M
Cap. Flow %
-1.03%
Top 10 Hldgs %
99.35%
Holding
17
New
1
Increased
3
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
SNGX icon
Soligenix
SNGX
+$1.83M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$842K
3
NTBL
Notable Labs, Ltd. Ordinary Shares
NTBL
+$240K
4
EVOK
Evoke Pharma
EVOK
+$144K

Top Sells

Rank Stock Value
1
KERX
Keryx Biopharmaceuticals Inc
KERX
+$1.42M
2
SMMT icon
Summit Therapeutics
SMMT
+$1.15M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$812K
4
LSTA icon
Lisata Therapeutics
LSTA
+$422K
5
VNRX icon
VolitionRx Ltd
VNRX
+$322K

Sector Composition

Rank Sector Weight
1 Healthcare 99.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
1
Abeona Therapeutics
ABEO
$345M
$37.4M 32.97%
94,391
– –
CRBP icon
2
Corbus Pharmaceuticals
CRBP
$170M
$27.4M 24.14%
128,566
+3,935
+3% +$842K
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$21.8M 19.2%
807,224
– –
AMPE
4
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$10.6M 9.31%
8,652
– –
NTBL
5
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$6.37M 5.61%
25,622
+1,033
+4% +$240K
KRYS icon
6
Krystal Biotech
KRYS
$9.88B
$3.16M 2.78%
300,000
– –
AVXL icon
7
Anavex Life Sciences
AVXL
$222M
$2.33M 2.06%
724,205
– –
SNGX icon
8
Soligenix
SNGX
$5.5M
$1.83M 1.62%
+3,629
New +$1.83M
VNRX icon
9
VolitionRx Ltd
VNRX
$12M
$1.03M 0.91%
17,577
-5,500
-24% -$322K
ALDX icon
10
Aldeyra Therapeutics
ALDX
$91.7M
$844K 0.74%
124,096
– –
EVOK
11
DELISTED
Evoke Pharma
EVOK
$622K 0.55%
1,910
+347
+22% +$144K
ADXSW
12
DELISTED
Advaxis Inc Warrants
ADXSW
$113K 0.1%
112,500
– –
ARCT icon
13
Arcturus Therapeutics
ARCT
$157M
– –
-114,864
Closed -$812K
LPCN icon
14
Lipocine
LPCN
$17.1M
– –
-1,471
Closed -$99K
LSTA icon
15
Lisata Therapeutics
LSTA
$15.2M
– –
-7,864
Closed -$422K
SMMT icon
16
Summit Therapeutics
SMMT
$10.6B
– –
-91,800
Closed -$1.15M
KERX
17
DELISTED
Keryx Biopharmaceuticals Inc
KERX
– –
-200,000
Closed -$1.42M

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Knoll Capital Management held 17 positions worth $113M, down 3% from $117M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Knoll Capital Management's Q4 2017 filing shows 1 new, 3 increased, 1 reduced and 5 closed positions. Its largest new stake was Soligenix: 3,629 shares worth $1.83M. The largest sale was Keryx Biopharmaceuticals Inc, an estimated $1.42M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Knoll Capital Management's largest Q4 2017 buy was Soligenix: 3,629 shares worth $1.83M.
  • Knoll Capital Management added most to Corbus Pharmaceuticals in Q4 2017, an estimated $842K increase.
  • Knoll Capital Management's biggest Q4 2017 reduction was VolitionRx Ltd, cutting an estimated $322K.
  • Knoll Capital Management fully exited Keryx Biopharmaceuticals Inc in Q4 2017, selling an estimated $1.42M.
  • Knoll Capital Management's ten largest holdings make up 99% of its $113M portfolio in Q4 2017.
  • Knoll Capital Management opened 1 new position and closed 5 in Q4 2017.
  • Knoll Capital Management's portfolio value fell 3% quarter-over-quarter to $113M.

Based on Knoll Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.